Connect Biopharma Reports First Quarter 2025 Financial Results and Provides Business Update
Provided By GlobeNewswire
Last update: May 15, 2025
Initiated Phase 2 Seabreeze STAT Asthma and Seabreeze STAT COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations in Asthma and COPD in May 2025; topline data expected in 1H 2026
Read more at globenewswire.com1.78
-0.21 (-10.55%)
Find more stocks in the Stock Screener
CNTB Latest News and Analysis
